MONTREAL, /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

Detailed price information for Aytu Biopharma Inc (AYTU-Q) from The Globe and Mail including charting and trades.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...